Lumos Diagnostics Receives Authorization for CoviDx™ SARS-CoV-2 Rapid Antigen Test in Canada
November 03 2021 - 8:02AM
Business Wire
Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care
(POC) diagnostic technologies, today announced that Health Canada
has granted Interim Order authorization for the Lumos CoviDx™
SARS-CoV-2 Rapid Antigen Test. The CoviDx test gives qualified
healthcare providers qualitative, easy-to-interpret results within
15-20 minutes in cases of suspected COVID-19 and when performing
serial testing of asymptomatic patients.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20211103005647/en/
The CoviDx test from Lumos Diagnostics
gives qualified healthcare providers in Canada qualitative,
easy-to-interpret results within 15-20 minutes in cases of
suspected COVID-19 and when performing serial testing of
asymptomatic patients. Visit lumosdiagnostics.com to learn more.
(Photo: Business Wire)
“As SARS-CoV-2 continues to evolve, rapid point-of-care testing
is a critical component of the Canadian public health response,”
said Rob Sambursky, MD, President and Chief Executive Officer of
Lumos Diagnostics. “Using CoviDx as part of routine testing and
triage protocols can help advance public health and safety in
Canada, while also supporting the important efforts underway to
ensure the continuity of commerce, tourism and education across the
country.”
CoviDx is authorized by Health Canada for use by qualified
healthcare professionals in evaluating symptomatic patients, and
for serial testing of patients without symptoms. The CoviDx test is
a stand-alone POC test that uses individual pre-filled extraction
reagent vials to make it easy to administer in any patient care
setting – without any additional instruments or equipment. The test
is compatible with both nasopharyngeal and the less invasive nasal
swab sample collection and provides a simple “yes/no” result.
With Health Canada’s Interim Order authorization, CoviDx is
available to qualified healthcare providers across the country
through Lumos’ distribution partners.
This announcement has been approved by the Lumos Disclosure
Committee.
About Lumos Diagnostics
Lumos Diagnostics specialises in rapid, cost-effective, and
complete point-of-care (POC) diagnostic test technology to help
healthcare professionals more accurately diagnose and manage
medical conditions. Lumos offers customised assay development and
manufacturing services for POC tests and proprietary digital reader
platforms. Lumos also directly develops, manufactures, and
commercialises novel Lumos-branded POC tests that target infectious
and inflammatory diseases.
For more information about Lumos Diagnostics and the CoviDx
SARS-CoV-2 rapid antigen test, visit lumosdiagnostics.com.
Forward-Looking Statements
This announcement contains forward-looking statements, including
references to forecasts. Forward-looking statements are not
guarantees of future performance and involve known and unknown
risks, uncertainties, assumptions, and other important factors,
many of which are beyond Lumos' control and speak only as of the
date of this announcement. Readers are cautioned not to place undue
reliance on forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211103005647/en/
Media Contacts (U.S. and Global): Jennifer Christiansen –
Lumos Diagnostics jennifer.christiansen@lumosdiagnostics.com +1 920
784 3153 Media Contact (Australia): Haley Chartres – H^CK
haley@hck.digital +61 423 139 163 Investor Contact: Matthijs
Smith ir@lumosdiagnostics.com +61 411 137 080 +61 3 9087 1598
Company Registered Office: Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd South Melbourne, VIC 3205 +61 3 9087
1598
Lumos Diagnostics (ASX:LDX)
Historical Stock Chart
From Oct 2024 to Nov 2024
Lumos Diagnostics (ASX:LDX)
Historical Stock Chart
From Nov 2023 to Nov 2024